The application for marketing authorization of the independently developed drug of the holding subsidiary was approved by the EU
February 7, 2025
Source: drugdu
27
On February 5, Fosun Pharma announced that the marketing authorization application (MAA) of slulizumab injection (i.e., anti-PD-1 monoclonal antibody) independently developed by the holding subsidiary Shanghai Fuhong Henlius Biotech Co., Ltd. and its holding subsidiaries (collectively referred to as "Fuhong Henlius") for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) was recently approved by the European Commission (i.e., the European Commission).
Accordingly, the drug has obtained centralized marketing authorization in all EU member states and Iceland, Liechtenstein and Norway (European Economic Area countries respectively), and has become the first anti-PD-1 monoclonal antibody approved by the EU for the treatment of extensive-stage small cell lung cancer (ES-SCLC).
https://finance.eastmoney.com/a/202502063311927270.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Analysis Report on Import and Export of Medical Devices in China February 7, 2025
- Starting from February 1st, the settlement method for centralized procurement consumables has changed February 7, 2025
- Haisike has been approved to conduct clinical trials of the innovative drug HSK39004 February 7, 2025
- Innovative drugs are expected to accelerate into hospitals, and the Class C medical insurance catalogue is about to be released February 7, 2025
- Keytruda sold $29.5 billion last year, and Merck suspended shipments of HPV vaccines to the Chinese market February 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
